ABIVAX - 2015 Full-Year Results and Progress Report
ABIVAX - 2015 Full-Year Results and Progress Report
March 15, 2016
aris, March 15th, 2016 - ABIVAX (Euronext Paris : FR0012333284 – ABVX), an emerging leader in developing and commercializing anti-viral drugs and therapeutic vaccines for infectious diseases like HIV/AIDS and chronic hepatitis B (CHB), today reported its full-year financial results for the year ended December 31, 2015, and provided a progress report on its activities. The financial statements for 2015 were approved by the company’s Board of Directors on March 14th, 2016. The financial statements have been audited, and the certification report is being prepared by the company’s external auditors.